Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck has reported positive results of Startmrk Phase III study that assessed the efficacy of Isentress (raltegravir) tablets versus efavirenz in combination therapy to treat naive adult HIV-1-infected patients.
Subscribe to our email newsletter
Isentress is an integrase inhibitor by Merck for the treatment of HIV-1 infection in treatment-naive and treatment-experienced adult patients as part of combination therapy.
The double-blind, randomized, active-controlled, 192 week Phase III non-inferiority study comprised 563 untreated HIV-1 infected adult patients who received either 400 mg Isentress orally twice-daily or 600 mg efavirenz orally once-daily.
The trial demonstrated that Isentress showed better efficacy compared to the regimen containing efavirenz as measured by the percentage of patients maintaining undetectable virus levels.
In addition, Isentress also showed a greater immunological effect as compared to the efavirenz regimen.